European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Genome Research Ltd., Saffron Walden

Innovation Champion GB Commercial # 35
Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Genome Research Ltd.
Wellcome Trust Sanger Institute

Identification

Chp
Companies House 02742969

Address

Hinxton, THE Sanger Centre, Wellcome Trust Genome Campus, Saffron Walden CB10 1SA, United Kingdom
London, United Kingdom

Corporate purpose

72.11
Research and experimental development on biotechnology

A) to Advance Research Into and Investigation of the Human Genome and to Publish the Useful Results of Such Research B) to Advance Scientific and Medical Research

Financials

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Marketing & Tech

Network

Loading network
CSV export

Quarterly Exports in CSV

Now available in CSV format and optimized for applications in AI and Analytics:
North Data's quarterly exports have become the industry standard for company information.

Publications

22 Oct 2025
Patent: Method of Characterising a DNA Sample
26 Sept 2025
Reg­is­tra­tion: 21/05/1993 · Chair: John-Arne Rottingen · Board (8) · Email · Legal form · Phone Number · A) to Advance Research Into and Investigation of the Human Genome and to Publish the Useful …
23 Jun 2025 also 11/07/2024, 05/07/2023, 07/07/2022, 02/07/2021, 10/07/2020, 27/06/2019, 02/07/2018, 28/06/2017
Confirmation statement made with no updates
5 Jun 2025 as Genome Research Ltd. LBG
EU funding: Genetic lethal interactions in replication licensing-defective cancer cells
12 May 2025
No longer Director: Daniel Mahony
5 May 2025 as Genome Research Ltd. LBG
EU funding (€260,348): Decoding the transcriptomic programs that define human macrophage function.
9 Jan 2025
Annual report for the year ending 30/09/2024 · Balance sheet for 30/09/2024
7 Jan 2025
Annual report for the year ending 30/09/2024 · Earnings statement for 30/09/2024 · 1,296 employees
6 Jan 2025 as Wellcome Sanger Institute
UK funding (£592,392): Deciphering the regulatory genetic code
6 Jan 2025 as Wellcome Sanger Institute
UK funding (£405,523): Molecular mechanisms conferring risk for colorectal cancer
Year 2024 in Epobase
7 European patent filings: Methods for the Accurate Detection of Mutations in Single Molecules of DNA …
30 Jul 2024
No longer Director: Cilla Snowball
10 Jun 2024
Director: John-Arne Røttingen · No longer Director: Paul J. R. Schreier
17 May 2024
Director: Michael Dunn
29 Apr 2024
No longer Director: Cheryl Anne Moore
23 Apr 2024
Director: Karen Chadwick
22 Apr 2024
Director: Mark Mccarthy, M. Newcombe-Ellis, Caroline Relton
1 Apr 2024 as Wellcome Sanger Institute
UK funding (£22,297): Open Access Block Award 2024 - Wellcome Trust Sanger Institute
26 Mar 2024
No longer Director: Gilean Mcvean
14 Mar 2024
Director's details changed for Cheryl Anne Moore
12 Mar 2024
Annual report for the year ending 30/09/2023 · Balance sheet for 30/09/2023
7 Feb 2024
Annual report for the year ending 30/09/2023 · Earnings statement for 30/09/2023 · 1,271 employees
1 Jan 2024 as Wellcome Sanger Institute
UK funding (£260,676): Storming Immune Monogenic Conditions through Multiomic and Gene Editing Approaches
29 Jun 2023 via Bridges to Development
EU funding (€3,553,502): STOP 2030: TOWARDS THE INTERRUPTION OF TRANSMISSION OF SOIL-TRANSMITTED HELMINTHS: PROMOTING IMPLEMENTATION OF RESEARCH RESULTS OF A FIXED-DOSE COMBINATION OF CO-FORMULATED …
10 May 2023
Address
17 Mar 2023 also 19/12/2017
Termination of appointment of Kay Elizabeth Davies as a director
7 Mar 2023
No longer Director: Jeremy Farrar
13 Feb 2023
Annual report for the year ending 30/09/2022 · Balance sheet for 30/09/2022
10 Feb 2023
Patent: BCL-2 Inhibitors and Aurora Kinase Inhibitors for Treating Cancer
10 Feb 2023
Patent: An IGF1R Inhibitor and an AKT Inhibitor for USE in the Treatment of Cancer
10 Feb 2023
Patent: Combination of Chek1 Inhibitor and TOP1 Inhibitor for Treating Colorectal Cancer
12 Jan 2023
Annual report for the year ending 30/09/2022 · Earnings statement for 30/09/2022 · 1,187 employees
2 Dec 2022 in Hor
EU funding (€2,497,298): Learning and modeling the molecular response of single cells to drug perturbations
25 Nov 2022 in Hor
EU funding (€62,500): Evolutionary Genomics of Unconventional Sex Chromosomes in Frogs
4 Oct 2022
Patent: Method of Generating a Library of Polynucleotide Molecules Encoding Guide Rnas
1 Oct 2022 as Wellcome Sanger Institute
UK funding (£1,150,307): Clonal dynamics and mutational landscape of normal and cancerous tissues in cancer predisposition syndromes
29 Sept 2022
Patent: Methods for Gene Editing
21 Sept 2022
Patent: Flow Cell Interface Adaptor
1 Sept 2022 in Ukri
UK funding (£690,574): Biodiversity Genomics Europe
2 Jul 2022 as Wellcome Sanger Institute
UK funding (£153,085): Genomics of Host-Parasite Coevolution: A Test of Arms Race and Red Queen Dynamics in a Wild Insect System
1 Apr 2022 as Wellcome Sanger Institute
UK funding (£28,730): Open Access Block Award 2022 - Wellcome Trust Sanger Institute
21 Mar 2022
Annual report for the year ending 30/09/2021 · Earnings statement for 30/09/2021 · 1,178 employees
11 Mar 2022
Annual report for the year ending 30/09/2021 · Balance sheet for 30/09/2021
1 Oct 2021 as Wellcome Sanger Institute
UK funding (£170,338): A CELL ATLAS OF THE DEVELOPING HUMAN SENSORY NERVOUS SYSTEM: INVESTIGATING DEVELOPMENT TO UNDERSTAND DISEASE
23 Sept 2021
Patent: Biomarkers
26 Aug 2021
Director: Cilla Snowball
22 Jul 2021
Termination of appointment of James Cuthbert Smith as a director
1 Jul 2021 in Hor
EU funding (€7,057,980): Building a reproducible single-cell experimental workflow to capture tumour cell persistence
25 Jun 2021
Patent: Culture of Organoids
21 May 2021 as Genome Research Ltd. LBG
EU funding (€224,934): Characterizing gene regulation in single cells through integration of scRNA-seq and scATAC-seq data with generic multi-modal prior information
1 Apr 2021 as Genome Research Ltd. LBG
EU funding (€212,934): Comparative modelling of organoids in the age of single-cell transcriptomics
1 Apr 2021 as Wellcome Sanger Institute
UK funding (£1,634,646): The Genomic Atlas of Dermatological Tumours (DERMATLAS)
22 Mar 2021
Annual report for the year ending 30/09/2020 · Balance sheet for 30/09/2020
25 Jan 2021
Annual report for the year ending 30/09/2020 · Earnings statement for 30/09/2020 · 1,055 employees
1 Nov 2020 via Mosaic Therapeutics Ltd.
UK funding (£789,026): Whole Genome Sequence-guided targeting of colorectal and oesophageal cancers
Year 2020 in Hor
5 EU fundings (€1,496,510): European Network Linking Informatics and Genomics of Helper T cells in Tissues …
Year 2020 in Epobase
5 European patent filings: Bacterial Compositions for the Treatment of Disease …
1 Jun 2020
Director's details changed for Dr Daniel Mahony
21 May 2020
Director: Daniel Mahony, Gilean Mcvean, Cheryl Anne Moore · No longer Director: Rolf Dieter Heuer
13 May 2020
Annual report for the year ending 30/09/2019 · Earnings statement for 30/09/2019 · 1,022 employees
10 Jan 2020
Annual report for the year ending 30/09/2019 · Balance sheet for 30/09/2019
9 Jan 2020
Appointment of Dr Jeremy Farrar as a director · Termination of appointment of David Lindsay Willetts as a director
4 Dec 2019
Director: Daniel Abrams
27 Nov 2019 in Hor
EU funding (€725,810): Human Gonad Developmental Cell Atlas
20 Nov 2019
Director: Nicole Mather
30 Oct 2019
Director: Paul J. R. Schreier · No longer Director: Kathleen Poole
8 Oct 2019
Patent: Animal Models and Therapeutic Molecules
2 Oct 2019 as Wellcome Sanger Institute
UK funding (£571,909): Using single-cell RNAseq to investigate human malaria parasite transmission dynamics
1 Jul 2019 as Wellcome Sanger Institute
UK funding (£119,461): BlobToolKit: Identification and analysis of non-target data in all Eukaryotic genome projects
28 May 2019
Appointment of Mrs Kathy Poole as a director
13 May 2019
Secretary: Nadia Meliti · No longer Secretary (1)
23 Apr 2019
Address
8 Apr 2019 as Wellcome Sanger Institute
UK funding (£185,651): Facilitating Deep Learning with Domain-Specific Knowledge
28 Mar 2019
Earnings statement for 30/09/2018 · 1,070 employees
8 Feb 2019
Patent: Oxyphenisatin Acetate, Oxyphenisatin and Bisacodyl for Treating Triple-Negative Breast Cancer
1 Feb 2019 in Hor
EU funding (€6,272,613): Genetics of Individuality
28 Jan 2019
Termination of appointment of Timothy James Livett as a director
25 Jan 2019
Annual report for the year ending 30/09/2018 · Balance sheet for 30/09/2018
6 Nov 2018
No longer Director: Jeremy Farrar
25 Jun 2018
Director: James Cuthbert Smith
1 May 2018 in Hor
EU funding (€158,520): LIFE LAB - Connecting Communities with the UK's leading Biotechnology and Life Science Hub
11 Apr 2018
Appointment of Professor Dame Kay Elizabeth Davies as a director
10 Apr 2018
Patent: Mouse Models and Therapeutic Molecules
9 Apr 2018
Patent: Novel Pneumococcal Vaccine
16 Mar 2018
Patent: Biomarker for Identifying Responders to Cancer Treatment
29 Dec 2017
Annual report for the year ending 30/09/2017 · Balance sheet for 30/09/2017
Year 2017 in Epobase
6 European patent filings: Hotspots for Chromosomal Rearrangement in Breast and Ovarian Cancers …
20 Dec 2017
Appointment of The Rt Hon Lord David Willetts as a director
18 Dec 2017
No longer Director: Patrick Vallance · Secretary (1)
1 Jul 2017 via Richmond Design & Marketing Ltd.
UK funding (£30,000): Cambridge Autonomous Bus System Feasibility Study
27 Jun 2017
Companies House - Filing
12 May 2017
Termination of appointment of Timothy James Rink as a director
1 Jan 2017 in Hor
EU funding (€20.2M): Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026
21 Dec 2016
Annual report for the year ending 30/09/2016 · Balance sheet for 30/09/2016
Year 2016 in Hor
5 EU fundings (€319,875): Towards enduring mouse resources and services advancing research into human health and disease …
3 Oct 2016 as Wellcome Sanger Institute
UK funding (£104,338): Next Generation sequencing of barcoded plasmodium falciparum mutants to dissect parasite fitness costs associated with drug resistance
22 Jul 2016
Patent: Nasal Sampling Methods
15 Jul 2016
No longer Director: Kevin Moses
28 Jun 2016
Annual return made up to 2016-06-28 no member list
11 Mar 2016
Patent: Biallelic Genetic Modification
25 Jan 2016
Auditor's resignation
19 Jan 2016 also 16/01/2015, 31/12/2013, 22/01/2013, 12/01/2012, 23/12/2010, 06/01/2010, 27/01/2009, 22/12/2007, 10/01/2007, 17/01/2006, 25/04/2005
Full accounts made up to 2015-09-30
Year 2015 in Hor
8 EU fundings (€305,458): European AIDS Vaccine Initiative 2020 …
20 Aug 2015
Annual return made up to 2015-08-20 no member list · Director's details changed for Professor Rolf Dieter Heuer
1 May 2015 as Wellcome Sanger Institute
UK funding (£350,043): Identifying sperm-egg receptor pairs essential for mammalian fertilization to select new targets for fertility treatment and contraception.
2 Apr 2015
No longer Director (1)
1 Apr 2015 as Wellcome Sanger Institute
UK funding (£338,538): SyntheticDNAStore. Synthetic biology innovation around design DNA molecules
1 Mar 2015 as Wellcome Sanger Institute
UK funding (£674,758): A long term resource to maximise the potential of laboratory mouse strains for medical research
10 Feb 2015
No longer Director (1)
4 Feb 2015
Satisfaction of charge 1 in full
6 Jan 2015
Director: Rolf Dieter Heuer
1 Dec 2014 in Hor
EU funding (€200,000): COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe
17 Sept 2014
Patent: Genomic Screening Methods Using RNA-Guided Endonucleases
11 Sept 2014
Patent: Methods of Modulating Platelet Aggregation, Thrombus Formation and Stability, or an Allergy Response
21 Aug 2014 also 20/08/2013, 22/08/2012, 23/08/2011
Annual return made up to 2014-08-20 no member list
20 Aug 2014
Director's details changed for Baroness N.N. · Director's details changed for Mr Simon …
2 May 2014
No longer Director (1)
2 Apr 2014
No longer Director (1)
18 Feb 2014
Patent: Nucleic Acid Marker Molecules for Identifying and Detecting Cross Contamination of Nucleic Acid Samples
2 Jan 2014
Address
29 Nov 2013
Director: Jeremy Farrar
1 Nov 2013 via The Automation Partnership (Cambridge) Ltd.
UK funding (£64,559): Personalised iPS Cell Culture System
4 Sept 2013
Patent: HIV-1 Detection
20 May 2013
Patent: Methods and Groups
15 Mar 2013
No longer Director (1)
8 Mar 2013
Word figurative mark: “e!“
27 Jul 2012
No longer Director (1)
8 Feb 2012
No longer Secretary (1)
14 Dec 2011
Patent: P53 Binding Polypeptide
5 Dec 2011
Patent: Compositions and Methods
1 Oct 2011 as Wellcome Sanger Institute
UK funding (£284,615): DTG Competition 2011/8
21 Sept 2011
Patent: Detecting Mutations
11 Jul 2011
Director: Kevin Moses
1 Jan 2011 via Base4 Innovation Ltd.
UK funding (£227,708): High-speed single molecule detection combining short DNA probes and barcoding bioinformatics for use as a new broad spectrum point-of-care diagnostic
30 Nov 2010
Director: Patrick Vallance
8 Nov 2010
No longer Director (1)
6 Oct 2010
No longer Director (1)
1 Oct 2010 as Wellcome Sanger Institute
UK funding (£229,607): DTG Competition 2010
7 Sept 2010
Patent: Cells and Methods for Obtaining Them
31 Aug 2010
Annual return made up to 2010-08-20 no member list · Director's details changed for Mr N.N. …
27 Aug 2010
Director's details changed for Professor N.N.
15 Jul 2010
Patent: Cells, Compositions and Methods
1 May 2010 as Wellcome Sanger Institute
UK funding (£566,691): Molecular and genetic dissection of Clostridium difficile spore-mediated transmission to identify points of intervention
19 Apr 2010
No longer Director (1)
1 Jan 2010 as Wellcome Sanger Institute
UK funding (£1,364,714): Defining the Human Synapse Proteome
2 Dec 2009
Patent: Method for USE in Polynucleotide Sequencing
1 Oct 2009 as Wellcome Sanger Institute
UK funding (£42,992): DTG 2009
24 Aug 2009 also 20/08/2008
Annual return made up to 20/08/09
19 May 2009
Director's change of particulars / N.N. / 16/05/2009
13 May 2009
Director (1)
1 Apr 2009 as Wellcome Sanger Institute
UK funding (£2,300,000): Generation of a Public Resource of Mouse Strain Sequences
11 Mar 2009
Patent: P53 Binding Polypeptide
2 Mar 2009
No longer Director (1)
2 Mar 2009 as Wellcome Sanger Institute
UK funding (£1,369,161): The porcine sex chromosomes: gene content sequence relationships and evolutionary implications for sex chromosome functionality
19 Feb 2009
Patent: Genetic Variation Associated with Coeliac Disease
18 Dec 2008
Director (1)
6 Dec 2007
Particulars of mortgage/charge
14 Sept 2007
Director's particulars changed
23 Aug 2007
Annual return made up to 20/08/07 · Director's particulars changed · Secretary's particulars changed …
2 May 2007 also 23/03/2006, 15/03/2006
New director appointed
10 Apr 2007 also 20/02/2007
Director resigned
21 Aug 2006
Annual return made up to 20/08/06 · Director's particulars changed · Secretary's particulars changed
1 Feb 2006 as Wellcome Sanger Institute
UK funding (£148,428): The iBAC genomic DNA expression library
23 Aug 2005
Annual return made up to 20/08/05 · Director's particulars changed
22 Aug 2005
Address
There are no publications matching your search.

Mentions

via Companies House in Psc
No longer BO: Mosaic Therapeutics Ltd. · No longer VR: Mosaic Therapeutics Ltd. · Shareholding: Mosaic Therapeutics Ltd. · VR (5 companies) · BO (4 companies) · Shareholdings (4 companies)
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Genome Research Ltd., Saffron Walden" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.